Methods: 1. We measured the expession of miR-148a using the technology of real-time qRT-PCR in pancreatic cancer cell lines PANC-1 and BXPC-3. After over-expressing miR-148a of the cells, MTT assays were used to determine the proliferation of the cancer cells, and migration assays were done using a modified transwell chamber system. 2. The putative downstream target gene of miR148a was found through bio-informatics analysis. Both panceratic cancer cell lines were transfected with the ErbB3 3′-UTR reporter plasmid. Then the activity of renilla and firefly luciferase

was assessed using the Alectinib clinical trial dual-luciferase reporter assay system, Taqman PCR assay was used to assess miR-148a expression. The expression of ErbB3 was detected using western blot analysis. 3. Both panceratic cancer cell lines were transfected with ErbB3 RNAi by using Lipofectamine2000.

The proliferation and migration of the cells were oberserved, and the results were compared with those of over-expressing miR-148a. Results:  1. MiR-148a was significantly downregulated in both cell lines, and the expression of miR-148a was correlated with the degree of malignancy. Functional studies indicated overexpression of miR-148a dramatically inhibits proliferation Fulvestrant solubility dmso and migration of pancreatic cancer cells. 2. Bio-informatic studies revealed that ErbB3 might be the direct target gene of miR-148a. Overexpression of miR-148a in pancreatic cancer cells could reduce the mRNA and protein levels of ErbB3, whereas miR-148a silencing significantly increased ErbB3 expression. Luciferase assays confirmed that miR-148a could directly bind to the site of 3′untranslated region of ErbB3. 3. Silencing of ErbB3 with RNA interference inhibited the growth of pancreatic cancer cells in vitro. MCE While the inhibition

of miR-148a slightly better than direct interference with siRNA in pancreatic cancer cell lines. Conclusion: In conclusion, miR-148a can inhibit cell proliferation and migration by targeting ErbB3. Our present results implicate the potential effects of miR-148a on treatment of pancreatic cancer. Key Word(s): 1. pancreatic cancer; 2. miR-148a; 3. ErbB3; Presenting Author: LIU PI Additional Authors: XIA LIANG, ZHANGWEI LONG, KEHUA JING, SU TAO, CHENYOU -XIANG, LUNONG HUA Corresponding Author: LIU PI Affiliations: Nanchang University Objective: To identify serum miRNAs differentially expressed in acute pancreatitis and evaluate their diagnostic potentials in disease detection and severity prediction. Methods: We first compared the serum miRNA expression profiles between 12 acute pancreatitis patients with various disease severities and three healthy controls. Differentially expressed serum miRNAs were identified and then validated in a larger cohort of patients and controls.